BLAUVELT, A.; WARREN, R.; REICH, K.; AL., et. Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, n. 2, p. 175, 2019. DOI: 10.25251/skin.3.2.15. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/532. Acesso em: 3 jul. 2024.